文献速递脊柱关节炎

超声特征在早期外周型脊柱关节炎中的诊断价值及治疗反应性

Diagnostic Value and Treatment Responsiveness of Ultrasonography Features in Correlation With Clinical Findings in Early Peripheral Spondyloarthritis.
PubMed 文献 · Arthritis Rheumatol · 2026-06-23

该研究基于CRESPA双盲安慰剂对照试验,对54例症状持续<12周的早期外周型脊柱关节炎患者进行标准化临床与超声评估。研究发现PD≥1和关节积液是肿胀关节的强预测因子,戈利木单抗显著促进超声病变消退;但临床压痛附着点中45%无超声异常,而19%无压痛附着点存在超声异常。

要点

  • PD≥1(OR 9.5)和超声关节积液(OR 8.3)是肿胀关节的强预测因子。
  • 戈利木单抗较安慰剂显著促进PD信号、滑膜肥厚和关节积液的消退。
  • 临床压痛附着点中45%无超声异常,而19%无压痛附着点存在超声异常。

核心结论

  • 超声在早期pSpA的附着点炎和关节炎中显示对TNFα抑制的高反应性,但受限于非特异性表现和临床对附着点炎的高估。

研究设计与样本

  • CRESPA试验为双盲、安慰剂对照试验,纳入54例症状持续<12周的早期pSpA患者,重复进行4对附着点和8对下肢关节的标准化临床与超声评估。

主要发现

  • 基线时滑膜肥厚不常见,且对临床评估无独立预测价值;PD≥1(OR 9.5)和超声关节积液(OR 8.3)是肿胀关节的强预测因子。
  • 戈利木单抗治疗较安慰剂显著预测PD信号、滑膜肥厚和关节积液的消退。
  • 临床压痛附着点中45%(21/46)无超声异常,而无压痛附着点中19%(72/386)存在超声异常。
  • 基线全部432个附着点中,仅附着点增厚(OR 10.89)和PD≥1(OR 5.94)预测压痛。
  • 戈利木单抗治疗还与附着点增厚、低回声和PD信号的消失相关。

临床怎么用

  • 超声可用于监测早期pSpA对TNFα抑制的治疗反应,但需注意临床附着点压痛可能高估炎症。

局限性

  • 超声表现存在非特异性,临床对附着点炎存在高估,需开发标准化评分系统和验证阈值以提高诊断准确性和治疗监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the diagnostic performance of ultrasonography features in the evaluation of enthesitis and arthritis in very early peripheral spondyloarthritis (pSpA). METHODS: The Clinical Remission in Peripheral Spondyloarthritis (CRESPA) trial was a double-blinded, placebo-controlled trial investigating induction of clinical remission in very early pSpA (symptom duration < 12 weeks) using tumor necrosis factor α (TNFα)-inhibition. Standardized clinical and ultrasonography evaluation of four pairs of entheses and eight pairs of lower limb joints were performed repeatedly in 54 patients. Analyses focused on the prevalence of ultrasonography features of joints and entheses, their correlation with clinical findings, and their response to treatment. RESULTS: At baseline, synovial hypertrophy was uncommon in this early pSpA cohort and showed no independent predictive value for clinical evaluation. In contrast, Power Doppler (PD) ≥1 (odds ratio [OR] 9.5) and ultrasonography joint effusion (OR 8.3) were strong predictors of a swollen joint. Golimumab treatment significantly predicted resolution of PD signal, synovial hypertrophy, and joint effusion on ultrasonography evaluation compared to placebo. Among entheses, 45% (21 of 46) of clinical tender sites displayed no ultrasonography abnormality, whereas 19% (72 of 386) of nontender entheses did. Across all 432 entheses at baseline, only entheseal thickening (OR 10.89) and PD ≥1 (OR 5.94) predicted tenderness. Treatment with golimumab was also associated with disappearance of entheseal thickening, hypoechogenicity, and PD signal. CONCLUSION: Ultrasonography in enthesitis and arthritis demonstrates high responsiveness to TNFα inhibition in early pSpA but is limited by nonspecific findings and clinical overestimation of enthesitis. Development of standardized scoring systems and validated thresholds is essential to improve diagnostic accuracy and treatment monitoring.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Van Hooste W, Braekman J, Renson T, et al. Diagnostic Value and Treatment Responsiveness of Ultrasonography Features in Correlation With Clinical Findings in Early Peripheral Spondyloarthritis. Arthritis Rheumatol. 2026. PMID: 42334234. doi:10.1002/art.70263

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。